drugset / Trial / NCT00451555

Enzastaurin Plus Fulvestrant vs. Placebo Plus Fulvestrant in Breast Cancer

NCT00451555

Phase 2 Completed 156 enrolled Eli Lilly and Company
RandomizedParallel-groupQuadruple-blindTreatment

Summary

The primary purpose of this study is to help answer the following research question: whether enzastaurin given together with fulvestrant can help participants who have breast cancer and make the tumor smaller or disappear and for how long.

Timeline

Start
2007-04-11
Primary completion
2010-12-28
Completion
2018-10-18

Drugs

EvaluationDrugModalityDoseRoute
Subject enzastaurin Small molecule 250 mg Oral
Subject enzastaurin Small molecule 500 mg Oral
Background Fulvestrant Small molecule 250 mg Intramuscular

Indications